The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2021 | Novel therapies on the horizon for lung cancer

Name: Novel therapies on the horizon for lung cancer
Uploaded: 2021-04-23T00:00:00Z
Duration: 2 min 40 s
Description: Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Samreen Ahmed • 23 Apr 2021

BTOG 2021

Lung Cancer Non-Small Cell Lung Cancer Antibodies CAR-T

Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.